| Business Summary | | Compugen
Ltd.
is
engaged
in
the
fields
of
computational
genomics
and
proteomics.
The
Company
combines
the
disciplines
of
mathematics
and
computer
science
with
molecular
biology
to
improve
the
understanding
of
genomics
and
proteomics,
the
study
of
genes
and
proteins.
Compugen's
expertise
in
these
areas
is
used
to
develop
core
technologies
and
platforms
that
are
the
basis
for
its
products
and
services.
These
products
and
services
are
designed
to
enable
life
scientists
to
significantly
enhance
their
research
efforts
in
drug
discovery,
therapeutic
and
diagnostic.
Compugen
provides
products
and
services
to
pharmaceutical,
biotechnology
and
other
life
science
organizations
through
corporate
solutions
and
to
individual
life
scientists
through
the
LabOnWeb.com
Website.
In
addition,
the
Company
is
commercializing
the
genes
and
proteins
that
are
discovered
through
its
drug
discovery
division. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Compugen
Ltd.
develops
proprietary
value
added
product
and
services,
including
``web-enhanced''
products,
and
provides
these
products
and
services
directly
to
individual
life
scientists
worldwide.
For
the
three
months
ended
3/31/01,
revenues
totalled
$2.2
million,
up
from
$859
thousand.
Net
loss
decreased
11%
to
$3.6
million.
Revenues
reflect
collaborations
with
Pfizer
Global
Research
and
Human
Genome
Sciences
Inc.
Earnings
were
offset
by
higher
R&D
and
marketing
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
2,907;
after
tax
earnings
were
-3,950. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | |
| Position | Martin Gerstel | Chairman | Eli Mintz | CEO,
Pres | Mor Amitai | CEO | Lior Ma'ayan | VP,
COO | Simchon Faigler | VP,
CTO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|